Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome

Am J Kidney Dis. 2015 Feb;65(2):342. doi: 10.1053/j.ajkd.2014.04.039.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Atypical Hemolytic Uremic Syndrome*
  • Cost of Illness*
  • Drug-Related Side Effects and Adverse Reactions / prevention & control*
  • Female
  • Hemoglobinuria*
  • Humans
  • Male
  • Quality of Life*
  • Withholding Treatment*

Substances

  • Antibodies, Monoclonal, Humanized